Breakthrough Treatment for Hypoparathyroidism Shows Positive Phase 3 Results

Positive results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) 1 receptor agonist, met its composite primary endpoint, demonstrating statistically significant and clinically meaningful results in adults with hypoparathyroidism. This breakthrough offers hope for patients with hypoparathyroidism, a rare endocrine disorder, showing potential to normalize serum calcium and reduce dependence on supplements.

Key Facts

• Eneboparatide (AZP-3601) met its composite primary endpoint in the CALYPSO Phase III trial AstraZeneca
• The treatment demonstrated statistically significant and clinically meaningful results in adults with hypoparathyroidism Drugs.com
• This investigational therapy shows potential to normalize serum calcium levels and reduce dependence on supplements for hypoparathyroidism patients

Why This Matters

This breakthrough offers hope for patients with hypoparathyroidism, a rare endocrine disorder that affects calcium regulation in the body. Currently, management of hypoparathyroidism relies heavily on calcium and vitamin D supplements, which can be challenging to balance and may lead to long-term complications. The positive Phase 3 results suggest that eneboparatide could provide a more targeted approach to treating the underlying hormone deficiency, potentially improving quality of life for patients with this rare condition.

What We Don't Know Yet

While this represents significant progress, continued implementation, scaling, and long-term monitoring will be essential to ensure sustained impact and address any emerging challenges. Key questions remain about long-term safety profile, real-world effectiveness outside clinical trials, accessibility and cost of the treatment once approved, and how it compares to existing management strategies for different patient populations.

Sources: AstraZeneca · Drugs.com
Published May 31, 2026 · Category: Health & Medicine